(Bloomberg) -- Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US Food and Drug Administration, offering patients ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. Into this crowded treatment landscape comes another new medicine as the FDA has signed off ...

Also Read: Sanofi Strengthens Its Immune System-Focused Pipeline With Around $2 Billion Dren Bio Deal By lowering AT, a protein that inhibits blood clotting, Qfitlia helps increase thrombin generation ...

Sanofi SA gained U.S. FDA approval for fitusiran as a first-in-class siRNA therapy for hemophilia. Branded Qfitlia, the antithrombin-lowering therapy is indicated for use as a prophylactic treatment ...

March 28 (Reuters) - The U.S. Food and Drug Administration approved French drugmaker Sanofi's (SASY.PA), opens new tab hemophilia therapy, introducing a new type of treatment administered every ...

The U.S. Food and Drug Administration said on Friday that it has approved Sanofi's (SNY) Qfitlia to treat bleeding in patients aged 12 and older with hemophilia A or B, with or without factor VIII ...

The FDA granted the approval of Qfitlia to Sanofi (SNY). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best ...

Sanofi's Qfitlia, approved a few days ago by the FDA, offers a competitive edge in the hemophilia market with fewer injections and broader applicability than rivals. Despite Qfitlia's promising ...

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition The U.S. Food and Drug Administration approved the use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of ...